Video

Dr. Iqbal on Second- and Third-Line Therapies in Gastric Cancer

Author(s):

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.

Physicians have a lot of options in the second-line setting, following the introduction of targeted therapies such as ramucirumab (Cyramza), says Iqbal. The VEGFR-2 inhibitor was FDA approved in 2014 as a treatment for patients with unresectable gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma following fluoropyrimidine- or platinum-containing therapy. In 2017, the agent was tested in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) in the frontline setting but failed to improve overall survival in patients with HER2-negative metastatic gastric or GEJ adenocarcinoma.

Moreover, immunotherapy has made an impact in the field. Currently, pembrolizumab (Keytruda) is FDA approved in the third-line setting for patients who are PD—L1 positive. These patients have about a 15% response rate, adds Iqbal. Durability has been seen in some patients, though not commonly. The goal now, says Iqbal, is to move immunotherapy into the first- and second-line settings.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University